Literature DB >> 11116062

High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men.

F Paultre1, T A Pearson, H F Weil, C H Tuck, M Myerson, J Rubin, C K Francis, H F Marx, E F Philbin, R G Reed, L Berglund.   

Abstract

Elevated levels of lipoprotein(a) [Lp(a)] and the presence of small isoforms of apolipoprotein(a) [apo(a)] have been associated with coronary artery disease (CAD) in whites but not in African Americans. Because of marked race/ethnicity differences in the distribution of Lp(a) levels across apo(a) sizes, we tested the hypothesis that apo(a) isoform size determines the association between Lp(a) and CAD. We related Lp(a) levels, apo(a) isoforms, and the levels of Lp(a) associated with different apo(a) isoforms to the presence of CAD (>/=50% stenosis) in 576 white and African American men and women. Only in white men were Lp(a) levels significantly higher among patients with CAD than in those without CAD (28.4 versus 16.5 mg/dL, respectively; P:=0.004), and only in this group was the presence of small apo(a) isoforms (<22 kringle 4 repeats) associated with CAD (P:=0.043). Elevated Lp(a) levels (>/=30 mg/dL) were found in 26% of whites and 68% of African Americans, and of those, 80% of whites but only 26% of African Americans had a small apo(a) isoform. Elevated Lp(a) levels with small apo(a) isoforms were significantly associated with CAD (P:<0.01) in African American and white men but not in women. This association remained significant after adjusting for age, diabetes mellitus, smoking, hypertension, HDL cholesterol, LDL cholesterol, and triglycerides. We conclude that elevated levels of Lp(a) with small apo(a) isoforms independently predict risk for CAD in African American and white men. Our study, by determining the predictive power of Lp(a) levels combined with apo(a) isoform size, provides an explanation for the apparent lack of association of either measure alone with CAD in African Americans. Furthermore, our results suggest that small apo(a) size confers atherogenicity to Lp(a).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11116062     DOI: 10.1161/01.atv.20.12.2619

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  55 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 2.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 3.  Lipoprotein(a): implications for clinical practice.

Authors:  Robert C Block; Thomas A Pearson
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

4.  Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zeynep Ozturk; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Transl Res       Date:  2011-02-05       Impact factor: 7.012

5.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

Review 6.  The role of non-LDL:non-HDL particles in atherosclerosis.

Authors:  Jere P Segrest
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 7.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

8.  Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels.

Authors:  Sonia López; Alfonso Buil; Jordi Ordoñez; Juan Carlos Souto; Laura Almasy; Mark Lathrop; John Blangero; Francisco Blanco-Vaca; Jordi Fontcuberta; José Manuel Soria
Journal:  Eur J Hum Genet       Date:  2008-06-18       Impact factor: 4.246

Review 9.  Plasma lipoprotein concentrations in ethnic populations.

Authors:  Karol E Watson
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 10.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.